临床肺科杂志
臨床肺科雜誌
림상폐과잡지
JOUNAL OF CLINICAL PULMONARY MEDICINE
2014年
9期
1670-1672
,共3页
保鹏涛%赵卫国%李芸%刘宇%周怡%汤丽萍
保鵬濤%趙衛國%李蕓%劉宇%週怡%湯麗萍
보붕도%조위국%리예%류우%주이%탕려평
乌司他丁%放射性肺损伤%肺功能
烏司他丁%放射性肺損傷%肺功能
오사타정%방사성폐손상%폐공능
ulinastatin%radiation-induced lung injury%pulmonary function
目的:观察乌司他丁在改善非小细胞肺癌患者放疗后肺功能中的作用。方法120名非小细胞肺癌患者随机双盲分入实验组和对照组,实验组在放疗开始前3天及放疗中前7天接受乌司他丁治疗,同时对照组患者使用安慰剂治疗。观察放疗后放射性肺损伤发生率及程度。患者在放疗开始前,放疗后第8、24周时行肺功能评估。结果放疗后实验组患者放射性损伤发生率及程度以及FEV1, DLCO和FVC等指标下降程度明显低于对照组,第8周时实验组FVC值明显低于对照组,在24周时FEV1, DLCO 和FVC下降程度明显低于对照组。结论乌司他丁能有效降低非小细胞肺癌患者放疗后放射性肺损伤发生率并减轻肺功能下降程度。
目的:觀察烏司他丁在改善非小細胞肺癌患者放療後肺功能中的作用。方法120名非小細胞肺癌患者隨機雙盲分入實驗組和對照組,實驗組在放療開始前3天及放療中前7天接受烏司他丁治療,同時對照組患者使用安慰劑治療。觀察放療後放射性肺損傷髮生率及程度。患者在放療開始前,放療後第8、24週時行肺功能評估。結果放療後實驗組患者放射性損傷髮生率及程度以及FEV1, DLCO和FVC等指標下降程度明顯低于對照組,第8週時實驗組FVC值明顯低于對照組,在24週時FEV1, DLCO 和FVC下降程度明顯低于對照組。結論烏司他丁能有效降低非小細胞肺癌患者放療後放射性肺損傷髮生率併減輕肺功能下降程度。
목적:관찰오사타정재개선비소세포폐암환자방료후폐공능중적작용。방법120명비소세포폐암환자수궤쌍맹분입실험조화대조조,실험조재방료개시전3천급방료중전7천접수오사타정치료,동시대조조환자사용안위제치료。관찰방료후방사성폐손상발생솔급정도。환자재방료개시전,방료후제8、24주시행폐공능평고。결과방료후실험조환자방사성손상발생솔급정도이급FEV1, DLCO화FVC등지표하강정도명현저우대조조,제8주시실험조FVC치명현저우대조조,재24주시FEV1, DLCO 화FVC하강정도명현저우대조조。결론오사타정능유효강저비소세포폐암환자방료후방사성폐손상발생솔병감경폐공능하강정도。
Objective To investigate the effect of ulinastatin on pulmonary function of patients with NSCLC after radiation therapy. Methods 120 patients with NSCLC were randomly divided into two double-blind groups. The treatment group was treated with ulinastatin for 3 days prior to and for the first 7 days of radiotherapy, and the control group was treated with placebo for 10 days. RILI and pulmonary function were evaluated at 8 and 24 weeks af-ter radiation therapy. Results No adverse toxicological effect of treatment with ulinastatin was observed. The inci-dence and grade of RILI were significantly lower in the treatment group than in the control group (P<0. 05). There was significant difference in FVC at the 8th week between the two groups (P<0. 05). Reductions in the values of FEV1 , DLCO and FVC from baseline and at the 24th week were significantly smaller in the treatment group than those in the control group (P<0. 05). Conclusion Ulinastatin can significantly reduce the incidence and grade of RILI and improve PF in the treatment of NSCLC patients after radiotherapy.